Post

New research · Geriatrics
Vaccines · 1w
Case-controlVaccines · 2026

Protection and Duration of 23-Valent Pneumococcal Polysaccharide Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older Adults with Low Vaccination Coverage: A Multicenter Matched Case-Control Study in China.

Tianchi Yang, Xingqiu Ying, Xiaoqing Wu … Yumin Tao
Read paper
GeriatricsCase-control

23-valent pneumococcal polysaccharide vaccination linked to fewer community-acquired pneumonia hospitalizations in older adults

Protection and Duration of 23-Valent Pneumococcal Polysaccharide Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older Adults with Low Vaccination Coverage: A Multicenter Matched Case-Control Study in China.

Tianchi Yang … Yumin Tao
Vaccines · 2026
Background

23-valent pneumococcal polysaccharide vaccine (PPV23) effectiveness against community-acquired pneumonia (community-acquired pneumonia) remains controversial, with critical gaps in low-coverage settings and beyond 5 years post-vaccination.

Methods

A multicenter matched case-control study was conducted across 14 hospitals in Eastern China (2018-2022).

n = 15,806 controls
Results

Vaccinated older adults had 22.5% lower hospitalization for lung infection than unvaccinated

VE 22.50 (95% CI 4.10 to 37.30)
null 0
4.10
37.30
CI excludes the null - significant
More results

Among 6645 cases and 15,806 controls, 5-year PPV23 coverage was 2.14% (cases) and 2.76% (controls).

More results

Protection was concentrated in non-severe community-acquired pneumonia (adjusted vaccine effectiveness = 25.7%, 95% CI: 7.0% to 40.7%), with no significant effect in severe community-acquired pneumonia (adjusted vaccine effectiveness = -11.7%, 95% CI: -115.1% to 42.0%).

“
Conclusion

PPV23 provides meaningful protection against community-acquired pneumonia hospitalization in elderly adults in low-coverage settings, only for non-severe disease. Waning efficacy beyond 5 years supports revaccination at that interval.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Cross-sectional
44.1%
had too much homocysteine in the blood, a far larger share than in dry AMD or healthy eyes
Cohort Study
56%
lost three or more lines on the eye-chart vision test
Cohort Study
33.3%
more treated eyes could see at least 20/150 by follow-up
Study
70%
degenerative holes had complete loss of the outer light-sensing retinal layers
Cohort Study
1.25 vs 1.90 logMAR
initial vision was better for patients who achieved better final eyesight
Cohort Study
HR = 3.12
Patients positive for both markers had about 3 times the progression rate
Cohort Study
16.46
average everyday-function score three months after surgery, up from before, meaning better function
Study
8 questions
key research questions identified for lower leg soft-tissue injuries in older adults